Vahid Aslanzadeh reflects on a talk by Professor Stephan Sanders, Director of the MRC CoRE in Therapeutic Genomics, at the UK Human Functional Genomics Initiative Scientific Symposium 2026 in a new article on Medium. 

Newborn screening for spinal muscular atrophy moves closer to nationwide coverage in England 

Anthony McGuigan receives an award at the ESHG Conference 2026

Professor Sarah Tabrizi gets royal recognition

The University of Oxford and King’s College London (King’s) have joined the Innovative Medicine and Precision Approaches to Clinical Trials (IMPACT) Network, an international collaboration of sites working together to accelerate clinical trial readiness and therapeutic development for autism through a large-scale natural history and clinical endpoint study.

The CoRE is proud to support the launch of Genes, Brains, and Breakthroughs, a new educational campaign designed to raise public awareness and understanding of neurodevelopmental disorders through a series of accessible, family-informed video resources.

YouTube: https://www.youtube.com/@MRCCoRETG
TikTok: https://www.tiktok.com/@genebrainbreakthrough
Instagram: https://www.instagram.com/genebrainbreakthrough/

Click through for more info!

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has opened its consultation on the Draft rare disease therapies regulatory framework.  The CoRE will be sending in a response, and notes that patients and the general public are also invited to respond.

For more, see https://www.gov.uk/government/consultations/draft-rare-disease-therapies-regulatory-framework 

Congratulations to Emilie Wigdor on receiving the Early Career Investigator Award from the International Society for Autism Research at INSAR 2026. This award recognises her impactful work on the role of common variants in rare neurodevelopmental conditions.

MRC CoRE TG namechecked as part England's national strategy for rare diseases in 2026

Nicky Whiffin was named in The Sunday Times Alternative Honours List of 2025, for her role in helping to discover the genetic basis of ReNU syndrome - a previously unexplained neurodevelopmental disorder.

Kyle Muldoon Jr has been named in the 2025 Nature's 10 list, as the first recipient of personalised CRISPR therapy.

Professor Sarah Tabrizi, UCL Site Lead for the MRC CoRE and member of the CoRE Brain Theme, has been named in Nature's 10 list.